ERBB2 and non-small cell lung carcinoma: There is emerging evidence of similarly beneficial CNS outcomes from T-DXd in NSCLC trials, specifically Destiny-Lung01 and Destiny-Lung02, where a pooled analysis demonstrated promising intracranial response of T-DXd in HER2-mutated NSCLC patients with BMETs [8].